These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 32870366)
21. High Dose Cytosine Arabinoside in the consolidation of adult acute myeloid leukemia. Rahman MH; Khan MA; Islam MS; Afrose S; Ara T Mymensingh Med J; 2012 Apr; 21(2):213-9. PubMed ID: 22561761 [TBL] [Abstract][Full Text] [Related]
22. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W; Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557 [TBL] [Abstract][Full Text] [Related]
23. Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study. Ravikumar D; Saju H; Choudary A; Bhattacharjee A; Dubashi B; Ganesan P; Kayal S Indian J Hematol Blood Transfus; 2022 Jan; 38(1):31-41. PubMed ID: 35125710 [TBL] [Abstract][Full Text] [Related]
24. Immunological characterization and antibacterial function of persisting granulocytes in leukemic patients receiving pulse cytosine arabinoside-consolidation chemotherapy on days 1, 3, and 5. Krauth MT; Florian S; Böhm A; Sonneck K; Agis H; Samorapoompichit P; Hauswirth AW; Sperr WR; Valent P J Immunol; 2006 Feb; 176(3):1759-68. PubMed ID: 16424206 [TBL] [Abstract][Full Text] [Related]
25. Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Kam G; Yiu R; Loh Y; Ang AL; Yueh LL; Goh YT; Wong GC Support Care Cancer; 2015 Mar; 23(3):643-9. PubMed ID: 25160495 [No Abstract] [Full Text] [Related]
26. Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Kim DS; Kang KW; Lee SR; Park Y; Sung HJ; Kim SJ; Choi CW; Kim BS Ann Hematol; 2015 Sep; 94(9):1485-92. PubMed ID: 25944346 [TBL] [Abstract][Full Text] [Related]
27. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Inaba H; Gaur AH; Cao X; Flynn PM; Pounds SB; Avutu V; Marszal LN; Howard SC; Pui CH; Ribeiro RC; Hayden RT; Rubnitz JE Cancer; 2014 Jul; 120(13):1985-92. PubMed ID: 24677028 [TBL] [Abstract][Full Text] [Related]
28. c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia. Kubo H; Imataki O; Kubo YH; Uemura M; Kadowaki N Int J Clin Oncol; 2019 May; 24(5):590-595. PubMed ID: 30604157 [TBL] [Abstract][Full Text] [Related]
29. Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study. Ye L; Gao L; Cheng Q; Guo F; He L; Yuan T; Zhu M; Ma Y; Pan M; Chu X; Ding M; Yu G Medicine (Baltimore); 2021 Jan; 100(3):e24273. PubMed ID: 33546048 [TBL] [Abstract][Full Text] [Related]
30. Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. Pugliese N; Salvatore P; Iula DV; Catania MR; Chiurazzi F; Della Pepa R; Cerchione C; Raimondo M; Giordano C; Simeone L; Caruso S; Pane F; Picardi M Cancer Med; 2017 Jul; 6(7):1500-1511. PubMed ID: 28556623 [TBL] [Abstract][Full Text] [Related]
31. Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli. Saini L; Rostein C; Atenafu EG; Brandwein JM BMC Infect Dis; 2013 Jun; 13():284. PubMed ID: 23800256 [TBL] [Abstract][Full Text] [Related]
32. The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study. Chen G; Yang J; Cao F; Zhou W; Gong D; Liu L; Zhou D Ann Transl Med; 2022 Aug; 10(16):858. PubMed ID: 36111020 [TBL] [Abstract][Full Text] [Related]
33. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939 [TBL] [Abstract][Full Text] [Related]
34. Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions. Lee SSF; Fulford AE; Quinn MA; Seabrook J; Rajakumar I Support Care Cancer; 2018 May; 26(5):1499-1504. PubMed ID: 29170868 [TBL] [Abstract][Full Text] [Related]
35. Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia. Shpilberg O; Haddad N; Sofer O; Raanani P; Berkowicz M; Chetrit A; Carter A; Ramot B; Tatarski I; Ben-Bassat I Leuk Res; 1995 Dec; 19(12):893-7. PubMed ID: 8632657 [TBL] [Abstract][Full Text] [Related]
36. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736 [No Abstract] [Full Text] [Related]
37. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986 [TBL] [Abstract][Full Text] [Related]
38. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980 [TBL] [Abstract][Full Text] [Related]
39. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report. Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644 [TBL] [Abstract][Full Text] [Related]
40. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]